# Variant Analysis Report #8

**Gene:** BRCA1

**Variant:** NM_007294.4:c.4963T>C

---

<think>
Okay, let's tackle this BRCA1 variant c.4963T>C (p.Ser1655Pro) using the ACMG/AMP 2015 guidelines and ClinGen SVI recommendations. First, I need to go through each of the criteria step by step.

Starting with PVS1, which is for variants in a critical splice site. The variant here is a missense, not a splice site, so PVS1 doesn't apply. Next, PS1-4. PS1 is about the presence in a disease-specific database. ClinVar has conflicting classifications, which might be a problem. But since it's conflicting, that might not support PS1. PS2 is population frequency. gnomAD has no data, so maybe that's a point for PS2? Wait, no, PS2 is about absence from controls. If it's not present in gnomAD, that could support PS2. But the data is "None," so maybe it's not available. Hmm, not sure. PS3 is functional studies, but there's no in vitro or in vivo data, so PS3 doesn't apply. PS4 is segregation in families, but there's no family data here. So PS1-4 might not be applicable.

Moving to PM1-6. PM1 is about population frequency. Again, gnomAD data is missing, so maybe not applicable. PM2 is conservation. The phyloP score is N/A, so can't assess. PM3 is de novo, but no data. PM4 is predicted to affect function. CADD is 0.998, which is low, and REVEL is 0.847, which is also low. These are below the thresholds for pathogenicity. So PM4 might not apply. PM5 is for variants in a gene where other variants are pathogenic. BRCA1 is a known tumor suppressor, so maybe PM5 applies? But the variant is missense, and without other evidence, it's unclear. PM6 is for co-occurrence with other pathogenic variants, but no data here.

PP1-5. PP1 is segregation in families, but no data. PP2 is for a gene where missense variants are typically pathogenic. BRCA1 is a known tumor suppressor, so PP2 might apply. PP3 is functional studies, but none available. PP4 is for other evidence, like patient data, but no info. PP5 is for de novo, which isn't present here.

BA1 is for a variant that is a known pathogenic variant, but ClinVar has conflicting classifications, so BA1 doesn't apply. BS1 is for population frequency. Since gnomAD has no data, maybe not applicable. BS2 is for a variant that is not observed in affected individuals. But again, no data. BS3 is for computational prediction, but CADD and REVEL are low, so maybe BS3 applies? Wait, BS3 is for variants with low pathogenicity prediction. Since the predictions are low, that would support a benign classification. But the user is asking for ACMG criteria, so maybe BS3 is a negative point. Wait, the ClinGen SVI says that for PS3/BS3, if the variant is in a gene where missense variants are typically pathogenic, then the prediction might be weighted. But here, the predictions are low, so BS3 might be applicable. However, since the gene is BRCA1, which is known for pathogenic missense variants, maybe the low prediction is less reliable. Hmm, this is a bit confusing.

BP1-7. BP1 is for population frequency. Since gnomAD has no data, maybe not applicable. BP2 is for a variant that is not in a known pathogenic region. The variant is in BRCA1, which is a known pathogenic gene, so BP2 might not apply. BP3 is for a variant that is not in a functional domain. The position is Ser1655. I need to check if this is in a functional domain. BRCA1 has several domains like BRCT, RING, etc. Ser1655 is in the BRCT domain? If so, that might be a functional domain. But without specific info, it's hard to say. BP4 is for a variant that is not in a known pathogenic variant. Since ClinVar has conflicting classifications, maybe not. BP5 is for a variant that is not in a known pathogenic variant. Again, conflicting data. BP6 is for a variant that is not in a known pathogenic variant. Not sure. BP7 is for a variant that is not in a known pathogenic variant. This is all a bit unclear.

Putting it all together, the main points are: no population data, conflicting ClinVar, low computational predictions, and no functional studies. Since the variant is in a known pathogenic gene, PP2 might apply, but the low predictions and conflicting classifications might lead to a VUS. However, the absence from gnomAD could be a point for PS2, but since the data is missing, it's not clear. The ClinGen SVI might adjust the strength of PS3/BS3, but without functional data, it's hard to apply. The final classification might be VUS, but I need to check all criteria again.
</think>

### **BRCA1 c.4963T>C (p.Ser1655Pro) 변이 해석 (ACMG/AMP 2015 기준 및 ClinGen SVI 권고안 적용)**

---

#### **1. PVS1 (Pathogenic Variant in a Splice Site)**
- **적용 여부**: **불충족**  
- **근거**: 변이는 **missense** 유형이며, 스플라이스 사이트에 위치하지 않음.  
- **결론**: PVS1 기준에 해당하지 않음.

---

#### **2. PS1-4 (Population Frequency, Functional Studies, Segregation, etc.)**
- **PS1 (Disease-Specific Database)**:  
  - **적용 여부**: **불충족**  
  - **근거**: ClinVar에서 **Conflicting_classifications_of_pathogenicity**로 분류됨. 병리성과 무해성의 충돌적 평가로 PS1 기준을 충족하지 않음.  
- **PS2 (Absence from Controls)**:  
  - **적용 여부**: **불확실**  
  - **근거**: gnomAD AF (전체/인종 최대) 및 동형접합 데이터가 **None**으로 제공되지 않음. 인구 집단에서의 빈도가 확인되지 않아 PS2 기준을 명확히 평가할 수 없음.  
- **PS3 (Functional Studies)**:  
  - **적용 여부**: **불충족**  
  - **근거**: in vitro/in vivo 기능 연구 데이터가 **N/A**로 제공되지 않음.  
- **PS4 (Segregation in Families)**:  
  - **적용 여부**: **불충족**  
  - **근거**: 가계 분리 데이터가 **N/A**로 제공되지 않음.  

---

#### **3. PM1-6 (Population Frequency, Conservation, De Novo, etc.)**
- **PM1 (Population Frequency)**:  
  - **적용 여부**: **불충족**  
  - **근거**: gnomAD 데이터가 **None**으로 제공되지 않음.  
- **PM2 (Conservation)**:  
  - **적용 여부**: **불충족**  
  - **근거**: phyloP 보존성 데이터가 **N/A**로 제공되지 않음.  
- **PM3 (De Novo)**:  
  - **적용 여부**: **불충족**  
  - **근거**: de novo 데이터가 **N/A**로 제공되지 않음.  
- **PM4 (Predicted to Affect Function)**:  
  - **적용 여부**: **불충족**  
  - **근거**:  
    - **CADD**: 0.998 (경미한 영향 예측, **pathogenicity threshold: 10 이상**).  
    - **REVEL**: 0.847 (경미한 영향 예측, **pathogenicity threshold: 0.5 이상**).  
    - **SpliceAI**: N/A.  
    - **결론**: 전산 예측이 병리성 기준에 미달함.  
- **PM5 (Known Pathogenic Variants in Gene)**:  
  - **적용 여부**: **불충족**  
  - **근거**: BRCA1은 병리적 변이가 흔한 유전자이지만, 해당 변이의 기능적 영향이 명확하지 않음.  

---

#### **4. PP1-5 (Segregation, Gene-Specific, Functional Studies, etc.)**
- **PP1 (Segregation in Families)**:  
  - **적용 여부**: **불충족**  
  - **근거**: 가계 분리 데이터가 **N/A**로 제공되지 않음.  
- **PP2 (Gene-Specific Missense Pathogenicity)**:  
  - **적용 여부**: **충족**  
  - **근거**: BRCA1은 **tumor suppressor** 유전자로, missense 변이가 병리성으로 분류되는 경우가 많음.  
- **PP3 (Functional Studies)**:  
  - **적용 여부**: **불충족**  
  - **근거**: 기능 연구 데이터가 **N/A**로 제공되지 않음.  
- **PP4 (Other Evidence)**:  
  - **적용 여부**: **불충족**  
  - **근거**: 환자-대조군 연구 데이터가 **N/A**로 제공되지 않음.  
- **PP5 (De Novo)**:  
  - **적용 여부**: **불충족**  
  - **근거**: de novo 데이터가 **N/A**로 제공되지 않음.  

---

#### **5. BA1 (Known Pathogenic Variant)**  
- **적용 여부**: **불충족**  
- **근거**: ClinVar에서 **Conflicting_classifications_of_pathogenicity**로 분류됨.  

---

#### **6. BS1-4 (Population Frequency, Functional Studies, etc.)**
- **BS1 (Population Frequency)**:  
  - **적용 여부**: **불충족**  
  - **근거**: gnomAD 데이터가 **None**으로 제공되지 않음.  
- **BS2 (Not Observed in Affected Individuals)**:  
  - **적용 여부**: **불충족**  
  - **근거**: 환자-대조군 연구 데이터가 **N/A**로 제공되지 않음.  
- **BS3 (Low Pathogenicity Prediction)**:  
  - **적용 여부**: **충족**  
  - **근거**:  
    - CADD (0.998) 및 REVEL (0.847)은 병리성 기준에 미달.  
    - ClinGen SVI 권고안: **PS3/BS3 강도 조절** 적용.  
    - BRCA1은 missense 변이가 병리성으로 분류되는 경우가 많으나, **낮은 예측 점수**는 BS3 기준에 해당.  
- **BS4 (Not in Known Pathogenic Region)**:  
  - **적용 여부**: **불충족**  
  - **근거**: 변이 위치 (Ser1655)가 BRCA1의 **BRCT 도메인**에 위치할 가능성이 있음 (기능적 영역).  

---

#### **7. BP1-7 (Population Frequency, Functional Studies, etc.)**
- **BP1 (Population Frequency)**:  
  - **적용 여부**: **불충족**  
  - **근거**: gnomAD 데이터가 **None**으로 제공되지 않음.  
- **BP2 (Not in Known Pathogenic Region)**:  
  - **적용 여부**: **불충족**  
  - **근거**: BRCA1은 병리적 변이가 흔한 유전자.  
- **BP3 (Not in Functional Domain)**:  
  - **적용 여부**: **불충족**  
  - **근거**: Ser1655는 BRCT 도메인에 위치할 가능성이 있음 (기능적 영역).  
- **BP4 (Not in Known Pathogenic Variant)**:  
  - **적용 여부**: **불충족**  
  - **근거**: ClinVar에서 **Conflicting_classifications_of_pathogenicity**로 분류됨.  
- **BP5 (Not in Known Pathogenic Variant)**:  
  - **적용 여부**: **불충족**  
  - **근거**: 동일한 근거.  
- **BP6 (Not in Known Pathogenic Variant)**:  
  - **적용 여부**: **불충족**  
  - **근거**: 동일한 근거.  
- **BP7 (Not in Known Pathogenic Variant)**:  
  - **적용 여부**: **불충족**  
  - **근거**: 동일한 근거.  

---

### **최종 분류 및 근거**
- **ACMG/AMP 기준**:  
  - **PP2 (Gene-Specific Missense Pathogenicity)**: 충족.  
  - **BS3 (Low Pathogenicity Prediction)**: 충족.  
  - **기타 기준**: 대부분 불충족 또는 불확실.  
- **ClinGen SVI 권고안**:  
  - PS3/BS3 강도 조절 적용: **낮은 예측 점수** (CADD/REVEL)가 병리성 기준에 미달.  
  - BRCA1의 **기능적 중요성**과 **missense 변이의 일반적 병리성**을 고려하되, **전산 예측의 한계**를 반영.  

---

### **최종 변이 분류**
- **분류**: **VUS (Variants of Uncertain Significance)**  
- **신뢰도**: **낮음**  
- **임상적 해석**:  
  - BRCA1은 병리적 변이가 흔한 유전자이지만, 해당 변이의 **기능적 영향**이 명확하지 않음.  
  - **전산 예측** (CADD/REVEL)은 병리성 기준에 미달.  
  - **ClinVar의 충돌적 평가**와 **gnomAD 데이터 부재**로 인해 **분류 불확실**.  
  - 추가 연구 (기능적 분석, 가계 분리, 대규모 집단 데이터)가 필요.  

--- 

**참고**: 이 해석은 현재 제공된 데이터에 기반한 것으로, 추가 증거가 있을 경우 재평가가 필요합니다.